全文获取类型
收费全文 | 8903篇 |
免费 | 864篇 |
国内免费 | 261篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 61篇 |
妇产科学 | 83篇 |
基础医学 | 693篇 |
口腔科学 | 134篇 |
临床医学 | 1373篇 |
内科学 | 731篇 |
皮肤病学 | 143篇 |
神经病学 | 1247篇 |
特种医学 | 873篇 |
外科学 | 1368篇 |
综合类 | 1537篇 |
预防医学 | 286篇 |
眼科学 | 509篇 |
药学 | 493篇 |
9篇 | |
中国医学 | 243篇 |
肿瘤学 | 195篇 |
出版年
2024年 | 46篇 |
2023年 | 344篇 |
2022年 | 351篇 |
2021年 | 639篇 |
2020年 | 551篇 |
2019年 | 406篇 |
2018年 | 333篇 |
2017年 | 352篇 |
2016年 | 309篇 |
2015年 | 307篇 |
2014年 | 512篇 |
2013年 | 565篇 |
2012年 | 485篇 |
2011年 | 507篇 |
2010年 | 476篇 |
2009年 | 395篇 |
2008年 | 360篇 |
2007年 | 357篇 |
2006年 | 398篇 |
2005年 | 320篇 |
2004年 | 318篇 |
2003年 | 288篇 |
2002年 | 235篇 |
2001年 | 176篇 |
2000年 | 132篇 |
1999年 | 126篇 |
1998年 | 106篇 |
1997年 | 105篇 |
1996年 | 75篇 |
1995年 | 44篇 |
1994年 | 56篇 |
1993年 | 40篇 |
1992年 | 29篇 |
1991年 | 43篇 |
1990年 | 28篇 |
1989年 | 29篇 |
1988年 | 31篇 |
1987年 | 24篇 |
1986年 | 21篇 |
1985年 | 26篇 |
1984年 | 16篇 |
1983年 | 5篇 |
1982年 | 18篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 4篇 |
1975年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
ICU深部真菌感染危险因素分析 总被引:5,自引:0,他引:5
目的分析我院ICU患者深部真菌感染的危险因素,并探讨其控制对策。方法对我院ICU近2年确诊的52例深部真菌感染患者的临床资料进行分析。结果发现深部真菌感染仍好发于肺部,其次为泌尿道,胃肠道居第三位。危险因素导致深部真菌感染机会增加。结论ICU患者深部真菌感染的发病率较高,应减少或避免可能导致真菌感染的各种危险因素,积极采取有效的防范措施。 相似文献
993.
《JACC: Cardiovascular Imaging》2021,14(11):2226-2236
ObjectivesThe goal of this study was to assess whether a deep learning estimate of age from a chest radiograph image (CXR-Age) can predict longevity beyond chronological age.BackgroundChronological age is an imperfect measure of longevity. Biological age, a measure of overall health, may improve personalized care. This paper proposes a new way to estimate biological age using a convolutional neural network that takes as input a CXR image and outputs a chest x-ray age (in years) as a measure of long-term mortality risk.MethodsCXR-Age was developed using CXR from 116,035 individuals and validated in 2 held-out testing sets: 1) 75% of the CXR arm of PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) (N = 40,967); and 2) the CXR arm of NLST (National Lung Screening Trial) (N = 5,414). CXR-Age was compared to chronological age and a multivariable regression model of chronological age, risk factors, and radiograph findings to predict all-cause and cardiovascular mortality with a maximum 23 years and 13 years of follow-up, respectively. The primary outcome was observed mortality; results are provided for the testing datasets only.ResultsIn the PLCO testing dataset, a 5-year increase in CXR-Age carried a higher risk of all-cause mortality than a 5-year increase in chronological age (CXR-Age hazard ratio [HR]: 2.26 [95% confidence interval (CI): 2.24 to 2.29] vs. chronological age HR: 1.77 [95% CI: 1.75 to 1.78]; p < 0.001). A similar pattern was found for cardiovascular mortality (CXR-Age cause-specific HR: 2.45 per 5 years [95% CI: 2.34 to 2.56] vs. chronological age HR: 1.82 per 5 years [95% CI: 1.74 to 1.90]). Similar results were seen for both outcomes in the NLST external testing dataset. Adding CXR-Age to the multivariable model resulted in significant improvements for predicting both outcomes in both testing datasets (p < 0.001 for all comparisons).ConclusionsBased on a CXR image, CXR-Age predicted long-term all-cause and cardiovascular mortality. 相似文献
994.
995.
Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 下载免费PDF全文
K. Kosaka M. Imamura C. N. Hayes H. Abe N. Hiraga S. Yoshimi E. Murakami T. Kawaoka M. Tsuge H. Aikata D. Miki H. Ochi H. Matsui A. Kanai T. Inaba K. Chayama 《Journal of viral hepatitis》2015,22(2):158-165
Daclatasvir (DCV) and asunaprevir (ASV) are NS5A and NS3 protease‐targeted antivirals respectively, currently under development for the treatment of chronic hepatitis C virus (HCV) infection. We analysed the relationship between pre‐existing drug‐resistant variants and clinical outcome of the combination treatment with DCV and ASV. Ten patients with HCV genotype 1b were orally treated with a combination of ASV and DCV for 24 weeks. The frequencies of amino acid (aa) variants at NS3 aa positions 155, 156 and 168 and at NS5A aa31 and 93 before and after treatment were analysed by ultra‐deep sequencing. We established a minimum variant frequency threshold of 0.3% based on plasmid sequencing. Sustained virological response (SVR) was achieved in 8 out of 10 patients (80%), and relapse of HCV RNA after cessation of the treatment and viral breakthrough occurred in the other two patients. Pre‐existing DCV‐resistant variants (L31V/M and/or Y93H; 0.9–99.4%) were detected in three out of eight patients who achieved SVR. Pre‐existing DCV‐resistant variants were detected in a relapsed patient (L31M, Y93H) and in a patient with viral breakthrough (Y93H); however, no ASV‐resistant variants were detected. In these patients, HCV RNA rebounded with ASV‐ and DCV‐ double resistant variants (NS3 D168A/V plus NS5A L31M and Y93H). While pre‐existing DCV‐resistant variants might contribute to viral breakthrough in DCV and ASV combination therapy, the effectiveness of prediction of the outcome of therapy based on ultra‐deep sequence analysis of pre‐existing resistant variants appears limited. 相似文献
996.
Hepatitis B virus quasispecies evolution after liver transplantation in patients under long‐term lamivudine prophylaxis with or without hepatitis B immune globulin 下载免费PDF全文
997.
998.
999.
目的评估丘脑底核脑深部电刺激(STN-DBS)对帕金森病的临床疗效。方法回顾性分析应用STN-DBS手术治疗的32例帕金森病病人的临床资料,在术前、术后3个月分别采用统一帕金森病评定量表(UPDRS)、抑郁自评量表(SDS)和症状自评量表(SCL-90)进行随访评估、心理状况问卷调查和分析。结果脉冲发生器开启后,32例病人的UPDRS日常活动和运动功能在"关"状态,平均改善率为51.7%和60.9%;在"开"状态下,平均改善率21.4%和22.3%。20例病人术前SDS评分50分,其SCL-90的抑郁、焦虑、躯体化、人际敏感、敌对、恐怖和偏执7个因子显著高于中国常模(P0.05)。术前与术后SCL-90抑郁、躯体化、恐怖、焦虑、精神病性因子有显著性差异(P0.05),人际敏感、偏执、敌对和强迫等因子无显著性差异(P0.05)。结论 STN-DBS可以改善帕金森病病人的运动功能,提高日常生活能力,还可以明显改善帕金森病伴抑郁病人的心理状况,是安全有效的治疗方法。 相似文献
1000.